Spur Therapeutics’ Post

WEBINAR ALERT! Tune in for an insightful session with my colleagues Jessica Koepke and João Cotovio to discover the applications of Ncyte® aCardiomyocytes in toxicity and gene modulation assays. In this webinar, you'll learn about the quality control and characterization of Ncyte® aCardiomyocytes, as well as examples of their applications in drug discovery and the advantages of using chamber-specific cardiomyocytes. Don't miss out on this opportunity to learn from experts in the field! Choose the session that best fits your time zone: For my European connections: Wednesday, August 28th at 3:30 PM CEST For my US connections: Wednesday, August 28th at 1:00 PM EDT Registration links in the comments below ⬇ #Cardiomyocytes #cardiacdisease #DrugDiscovery

WEBINAR ALERT! Join us for an insightful session with Jessica Koepke and João Cotovio to discover the applications of Ncyte® aCardiomyocytes in toxicity, and gene modulation assays. In this webinar, you will learn about the quality control and characterization of Ncyte® aCardiomyocytes, as well as examples of their applications in drug discovery and the advantages of using chamber-specific cardiomyocytes. Don't miss out on this opportunity to learn from experts in the field! Choose the session that best fits your time zone: For our European audience: Wednesday, August 28th at 3:30 PM CEST Register here: https://lnkd.in/dVeqGTNX For our US audience: Wednesday, August 28th at 1:00 PM ET Register here: https://lnkd.in/d4c72SJy Secure your spot and gain valuable insights! #Webinar #Cardiomyocytes #cardiacdisease #DrugDiscovery #CellBasedAssay #Ncardia

Get the latest on pediatric cell and gene clinical research in this webinar hosted by Institute for Advanced Clinical Trials for Children (I-ACT for Children) on June 25. Advarra's Daniel Eisenman PhD, CBSP will share his biosafety insights with the panel. #clinicaltrials #celltherapy #genetherapy

Precision and patient-focus are key for cell, gene and immunotherapy clinical studies. At Advanced Clinical, our team understands the complexities of these trials. Learn how our team can make sure your immunotherapy study is set up for success: https://hubs.la/Q02z-3Vm0 #Immunotherapy #CellGeneTherapy #CellTherapy #GeneTherapy #ClinicalTrials

Thank you Lung-I Cheng for facilitating this robust discussion at Reuters Events Pharma about the value of #patient engagement in #cell and #gene therapy development. Key takeaways included: *Innovative study designs, such as leveraging #RWE, is needed to develop treatments for rare diseases which often have small patient populations. *Leveraging information from #FDA's patient focused drug development meetings is important to understanding the patient experience. *The rapid development of #CGTs is a paradigm shift for many regulating bodies, and risk-based flexability is needed to ensure timely #patient #access. *Long-term patient follow up remains a challenge, but the value of capturing patient #data remains a priority. Fellow Panelists: Olga Granaturova, Co-founder, President, PriveBio Jeffrey Meckler, Chief Executive Officer, Indaptus Therapeutics Jason Lott, MD MSHP MHS FAAD, VP, Global Integrated Evidence Generation, Specialty Medicine, Integrated Care, and Cell-Gene Therapy, Bayer Special thanks to my colleagues American Society of Gene & Cell Therapy for supporting my participation at events on this important topic. #ASGCT #ASGCTadvocacy #CellTherapy #GeneTherapy

Dear Network, I will be attending the American Society of Gene & Cell Therapy annual meeting in Baltimore and presenting a poster:   Novel Animal Models to Evaluate Preclinical Studies of Thalassemia Thursday, May 9th, 12:00 PM Session Title: Genetic Disorders of the Blood and Immune System Final Abstract Number: 1160 Looking forward to meeting and connecting with you. Let me know if you're interested in setting up a time to chat. #asgct #asgct24 #cellandgenetherapy #celltherapy #mousemodels #preclinicalresearch #thalassemia

If you are working in Gene Therapeutics and use Adeno Associated Viruses - don't miss out on the opportunity to pick the brains of Jordi and Benoit at ESGCT in Brussels Oct 24-27. Perhaps our technology, based upon the reporter gene assay format, that allows to assess and quantify the presence, activity, and function of a therapeutic AAV vector might be helpful? This technology can be adapted for many applications throughout the drug development phases including drug manufacturing processes such as the quantification of vector potency and functionality or the detection of pre-existing neutralizing anti-drug antibodies (NAb). Complicated to perform? No, it is performed in an easy and time-saving manner.

Dyno Therapeutics launches its second product, Dyno eCap1 for the eye today at ESGCT. Congrats to the team on yet another best-in-class capsid for the treatment of genetic disease and beyond. Better delivery=Better treatments. Key Data on Dyno eCap 1 Technology -- The Dyno eCap 1 vector exhibits 80-fold better transduction to the retina compared to the commonly used AAV2 capsid. -- The Dyno eCap 1 vector transduces the retina better than a cohort of external engineered IVT capsids, supporting a field-leading profile. -- The Dyno eCap 1 vector consistently transduces cell types broadly across retinal layers, including rod cel, bipolar cells and retinal ganglion cells. -- The Dyno eCap 1 vector was validated in cynomolgus monkey (Macaca fascicularis), the most relevant NHP model for predicting translatability to human clinical trials. Improved performance is highly consistent across bulk RNA-seq, single-cell RNA-seq and histology.

Dyno Therapeutics launches its second product, Dyno eCap1 for the eye today at ESGCT. Congrats to the team on yet another best-in-class capsid for the treatment of genetic disease and beyond. Better delivery=Better treatments. Key Data on Dyno eCap 1 Technology -- The Dyno eCap 1 vector exhibits 80-fold better transduction to the retina compared to the commonly used AAV2 capsid. -- The Dyno eCap 1 vector transduces the retina better than a cohort of external engineered IVT capsids, supporting a field-leading profile. -- The Dyno eCap 1 vector consistently transduces cell types broadly across retinal layers, including rod cel, bipolar cells and retinal ganglion cells. -- The Dyno eCap 1 vector was validated in cynomolgus monkey (Macaca fascicularis), the most relevant NHP model for predicting translatability to human clinical trials. Improved performance is highly consistent across bulk RNA-seq, single-cell RNA-seq and histology.